Do GLP-1 drugs really make you lose 40% muscle mass?

What's this video probably claiming?

Based on the caption, @nutritionbabe is making a case that people on GLP-1 medications like semaglutide (Ozempic, Wegovy) are losing a disproportionate amount of muscle mass alongside fat, and that resistance training is the underutilized fix. The specific stat cited, that roughly 40% of weight lost on GLP-1s comes from lean mass rather than fat, is a figure that has circulated in fitness and nutrition spaces for the past two years. The creator appears to be framing this as a warning, positioning exercise, and likely protein intake and supplementation, as the corrective. The hashtags suggest this is aimed at a general wellness audience, not a clinical one. That framing matters, because the 40% figure is real but needs significant context that a short-form video almost certainly does not provide.

What does the science actually show?

The lean mass loss concern is not invented. In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks, and body composition data showed roughly 39% of that loss came from lean mass. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed similar patterns. However, context is everything here. First, lean mass loss as a proportion of total weight loss is not unique to GLP-1s. Caloric restriction without exercise typically produces 25-35% lean mass loss regardless of mechanism. Second, the absolute muscle loss matters more than the percentage. Losing 4 lbs of muscle while losing 10 lbs of fat-heavy total weight is a different clinical picture than losing 4 lbs of muscle with minimal fat change. Third, studies specifically incorporating resistance training alongside GLP-1 use, like Lundgren et al., 2024 in Obesity, showed significantly attenuated lean mass loss.

Where does the social media noise diverge from clinical reality?

The problem with the 40% framing on TikTok is that it gets stripped of its denominators fast. If someone loses 50 lbs on semaglutide, 40% lean mass loss sounds catastrophic. But if that person was carrying 80 lbs of excess fat, and their lean mass loss is 5-7 lbs over 12 months, the clinical picture is far less alarming, especially if function and strength are maintained. What also gets lost is that GLP-1 medications appear to reduce visceral fat preferentially, which is metabolically beneficial in ways that raw lean mass numbers do not capture. There is also conflation happening between lean mass and muscle mass specifically. Lean mass includes water, glycogen, and organ tissue. Glycogen depletion alone, common during caloric restriction, shows up as lean mass loss on DEXA scans without representing true muscle fiber loss. Creators who skip this nuance are not lying, but they are simplifying in ways that can drive unnecessary fear or supplement purchases.

What should you actually know?

Resistance training during GLP-1 therapy is genuinely well-supported. A 2024 analysis in the Journal of Cachexia, Sarcopenia and Muscle found that combining progressive resistance training with GLP-1 treatment preserved lean mass significantly better than GLP-1 alone. Protein intake above 1.2g per kg of body weight also appears to be protective based on current evidence. What you should be skeptical of is any creator using the muscle loss concern to funnel you toward specific supplements without discussing that the comparison baseline, caloric restriction without GLP-1s, also produces lean mass loss in similar ranges. The resistance training message is correct. The framing that GLP-1s are uniquely destructive to muscle is not well-supported. If you are on a GLP-1 and concerned about muscle preservation, that is a conversation worth having with a prescribing clinician, not something to solve through a TikTok-recommended product stack.